Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5865739 | 1.00 | MAPT (0.46) | MAPTALDH1A1PKMHPGDHSD17B10 | |
| SCHEMBL6212655 | 1.00 | MAPT (0.46) | MAPTALDH1A1PKMHPGDHSD17B10 | |
| SCHEMBL5865743 | 1.00 | MAPT (0.46) | MAPTALDH1A1PKMHPGDHSD17B10 | |
| SCHEMBL4037553 | 0.88 | MAPT (0.45) | MAPTALDH1A1PKMHPGDHSD17B10 | |
| SCHEMBL4044762 | 0.88 | MAPT (0.45) | MAPTALDH1A1PKMHPGDHSD17B10 | |
| SCHEMBL4044767 | 0.88 | MAPT (0.45) | MAPTALDH1A1PKMHPGDHSD17B10 | |
| SCHEMBL14033291 | 0.76 | AR (0.53) | MAPTALDH1A1PKMHPGDHSD17B10 | |
| SCHEMBL7246754 | 0.76 | AR (0.53) | MAPTALDH1A1PKMHPGDHSD17B10 | |
| SCHEMBL13964571 | 0.73 | AR (0.42) | MAPTALDH1A1PKMHPGDHSD17B10 | |
| SCHEMBL3187767 | 0.72 | TSHR (0.62) | MAPTALDH1A1PKMHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001911-B2 | Fused cyclic modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-21 | — | — | US | claimed |
| US-20030114420-A1 | Fused cyclic modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2003-06-19 | — | — | US | claimed |
| US-7001911-B2 | Fused cyclic modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114420-A1 | Fused cyclic modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR3C1 | MAPT 4504/4885ALDH1A1 4518/4885PKM 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.